Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFIRINOX and Gemcitabine/IMRT in Borderline Resectable Pancreatic Cancer
NCT01661088Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jun 2011
- Primary completion
- Aug 2017
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin and gemcitabine in pancreatic cancer (PC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Percentage of Patients That Underwent an R0 Resection at 6 months. Started Jun 2011; status: completed.
02
Drugs
fluorouracilirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatingemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01661088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01661088.